Can gene therapies for haemophilia defend their high price tags?
Pharmaceutical Technology
NOVEMBER 9, 2022
On November 2, the Institute for Clinical and Economic Review (ICER) released its updated evidence aimed at measuring the clinical effectiveness and cost of the two haemophilia gene therapies. A previous October 2020 report concluded that longer-term safety and efficacy were needed to update health-benefit price benchmarks.
Let's personalize your content